For informational purposes only — not investment advice

← Back to signals

INSM

LONGINSIDER SELL

Insmed Inc

Research: Finviz ↗·Perplexity ↗

🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.

Funds
3
Score
4.08
vs SPY
+15.9%
Stock return (since Q-end)
+15.3%
SPY return (since Q-end)
-0.7%
Current price
$122.88
Days to cover (short int.)
6.5d↓-13.9%
as of 2026-09-30 · shares short vs 2026-06-30

News Summary

Neutral

Insmed delivered strong commercial execution in H2 2026 with BRINSUPRI revenues accelerating sequentially (49% Q2, 29% Q3) and raising full-year guidance twice, positioning the drug to surpass $1 billion in annual sales. However, this revenue outperformance was offset by wider-than-expected adjusted losses, a CFO transition, and a 12.66% price target cut from Barclays, signaling valuation concerns despite operational momentum.

Red flags

  • •Adjusted losses wider than expected despite revenue beat
  • •CFO departure announced October 5, 2026 (though orderly transition through October 30)
  • •Barclays price target cut 12.66% on September 30, suggesting valuation model compression despite strong revenue growth

Funds Buying (3)

FundManagerShares Held∆ SharesPosition Value% of FundQoQStatus
Maverick CapitalLee Ainslie2.2M+2.2M$229M2.1%—NEW
Duquesne Family OfficeStanley Druckenmiller1.4M+271K$152M3.5%+23%Existing
Point72Steve Cohen537K+537K$57M<0.1%—NEW

Shares Held and Position Value reflect total quarter-end holdings. ∆ Shares is the change from the prior quarter. % of Fund is the position's share of the fund's reported equity portfolio — it drives the size weighting in the conviction score.

Portfolio Context

Where INSM ranks in each buying fund's book, and the positions immediately around it. What a holding sits next to often says more about the thesis than the position size does.

Duquesne Family Office

position #4 of this fund's book

  1. 1Natera Inc$865M
  2. 2Taiwan Semiconductor Manufac$282M
  3. 3Stmicroelectronics N V$232M
  4. 4Insmed Inc$152M
  5. 5Ypf Sociedad Anonima$143M
  6. 6Amazon Com Inc$129M
  7. 7Bbb Foods Inc$121M
Maverick Capital

position #23 of this fund's book

  1. 20MONSTER BEVERAGE CORP NEW$253M
  2. 21DPC HOLDINGS PLC$252M
  3. 22SNOWFLAKE INC$249M
  4. 23INSMED INC$229M
  5. 24SHERWIN WILLIAMS CO$198M
  6. 25CAMDEN PPTY TR$195M
  7. 26VULCAN MATLS CO$188M

Values are quarter-end position sizes. Shown only for funds where INSM ranks inside their 40 largest equity positions — below that, neighbouring names carry no signal. Adjacency is an inference about a fund's reasoning, not a disclosure of it.

Insider Activity

NameTitleTypeSharesPriceValueFiledSrc
Brennan David R—SELL25K$124.00$3.10M2026-09-09↗
SHAROKY MELVIN MD—SELL5K$127.53$0.64M2026-08-17↗
Adsett RogerChief Operating OfficerSELL240K$133.27$31.96M2026-08-10↗
Flammer Martina M.D.Chief Medical OfficerSELL9K$127.00$1.13M2026-08-06↗
Flammer Martina M.D.Chief Medical OfficerSELL18K$129.40$2.37M2026-08-06↗
Lewis WilliamChair and CEOSELL5K$105.62$0.51M2026-07-23↗
Lewis WilliamChair and CEOSELL6K$106.43$0.62M2026-07-23↗
Lewis WilliamChair and CEOSELL5K$116.55$0.58M2026-07-09↗
Lewis WilliamChair and CEOSELL2K$117.62$0.27M2026-07-09↗
Lewis WilliamChair and CEOSELL3K$118.52$0.40M2026-07-09↗
Flammer Martina M.D.Chief Medical OfficerSELL5K$109.02$0.53M2026-07-06↗
Flammer Martina M.D.Chief Medical OfficerSELL7K$110.60$0.82M2026-07-06↗

Beneficial Ownership (13D/13G)

FilerFormShares% of ClassFiledSrc
Darwin Global Management, Ltd.SC 13G/A6.4M3.0%2026-08-14↗
FMR LLCSC 13G/A16.1M7.4%2026-08-06↗
JPMORGAN CHASE & CO.SC 13G/A10.4M4.7%2026-07-22↗
Darwin Global Management, Ltd.SC 13G/A16.8M7.8%2026-05-15↗
FMR LLCSC 13G13.1M6.1%2026-05-06↗
Vanguard Capital ManagementSC 13G11.5M5.3%2026-04-30↗

SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.